Seattle Genetics (SGEN) Tops Q4 EPS by 59c, Revenues Beat; Offers FY20 Sales Outlook Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Seattle Genetics Reports Fourth Quarter and Full Year 2019 Financial Results
February 6, 2020 4:02 PM EST-ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $627.7 Million in 2019, Including $166.2 Million in the Fourth Quarter-
-PADCEV (Enfortumab Vedotin-ejfv) Granted Accelerated Approval by FDA for Patients with Locally Advanced or Metastatic Urothelial Cancer Following Platinum-based Chemotherapy and a PD-1 or PD-L1 Inhibitor; U.S. Commercial Launch Underway-
-Tucatinib Applications for Approval Submitted to the FDA and EMA for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer-
-Conference Call Today at 4:30 p.m. ET-
BOTHELL,... More
